Drug Transporter (DT) Information

General Information of DT
DT ID DTD0455
Gene Name SLC6A3
Protein Name Sodium-dependent dopamine transporter
Gene ID
6531
UniProt ID
Q01959
TCDB ID
2.A.22.1.3
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 4XPB_A

Identity: 55.354%

Minimized Score: -1503.772 kcal/mol

Detail: Structure Info

Synonyms DA transporter; DAT; DAT1; PKDYS; PKDYS1; SLC6A3; Solute carrier family 6 member 3
DT Family Neurotransmitter:Sodium Symporter (NSS) Family ;
Tissue Specificity Highly expressed in substantia nigra.
Function This transporter can terminate the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Disease(s) Parkinson's Disease [ICD-11: 8A00.0]
Endogenous Substrate(s) Cl-; Na+
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            4 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Amphetamine
 Approved Drug Info Attention deficit hyperactivity disorder 6A05 [1]
Benztropine
 Approved Drug Info Dystonia 8A02 [2]
Brexpiprazole
 Approved Drug Info Schizophrenia 6A20 [3]
Dopamine
 Approved Drug Info Parkinson's Disease 8A00.0 [4]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Bretylium
 Withdrawn Drug Info Ventricular fibrillation BC71.1 [5]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Dopamine
681
EM Info Identified using the adults with attention-deficit hyperactive disorder [6]
References
1 Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
2 Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J Pharmacol Exp Ther. 2014 Jan;348(1):106-15.
3 Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028.
4 Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
5 Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem. 1999 Feb 19;274(8):4876-82.
6 Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol Psychiatry. 2016 Jul;21(7):872-84.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.